Oxidation: Methionine residues (Met14 and Met125 in HGH) are susceptible to oxidation, especially in the presence of peroxides or metal ions
TABLE 2 Pharmacokinetic parameters of BPC157 in rats following intramuscular administrations of doses ranging between 5 and 120 g/kg (mean SD, n = 6)
PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
Virtually all of the robust evidence for BPC-157 comes from animal studies, not human clinical trials
Key notes are as follows: Ingredient Compatibility Taboos : Avoid compounding with caprylyl hydroxamic acid, EDTA-2Na, carnosine, glycine, hydroxyl/ammonium ion-containing substances, glucose, allantoin, aldehyde group-containing compounds and other ingredients
